<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="10.1016/j.lfs.2020.118105118105 : Article An updated insight into the molecular pathogenesis," exact="secondary" post="complications and potential therapeutics of COVID-19 pandemic JamwalSumita1GautamAkashb1ElsworthJohnaKumarMandeepcChawlaRakeshdKumarPuneeteâ�Ž[a], [b],"/>
 <result pre="[b], [c], [d], [e], â�ŽCorresponding author at: Department of Pharmacology," exact="Central" post="University of Punjab, Bathinda, Punjab 151001, India. 1Contributed equally,"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="long as the COVID-19 resource centre remains active. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) is an unprecedented disease caused by highly"/>
 <result pre="remains active. Abstract Coronavirus disease 2019 (COVID-19) is an unprecedented" exact="disease" post="caused by highly pathogenic SARS-CoV-2 and characterized by extreme"/>
 <result pre="disease caused by highly pathogenic SARS-CoV-2 and characterized by extreme" exact="respiratory" post="deterrence, pneumonia and immune damage. The phylogenetic analysis demonstrated"/>
 <result pre="by highly pathogenic SARS-CoV-2 and characterized by extreme respiratory deterrence," exact="pneumonia" post="and immune damage. The phylogenetic analysis demonstrated the sequence"/>
 <result pre="sequence similarity of SARS-CoV-2 with other SARS-like bat viruses. The" exact="primary" post="source and intermediate host are not yet confirmed, although"/>
 <result pre="SARS-CoV-2 with other SARS-like bat viruses. The primary source and" exact="intermediate" post="host are not yet confirmed, although transmission from human"/>
 <result pre="the lungs, heart, brain, and kidneys. As reported recently, numerous" exact="secondary" post="complications i.e., neurological, nephrological, cardiovascular, gastrointestinal, immune, and hepatic"/>
 <result pre="cardiovascular, gastrointestinal, immune, and hepatic complications, are associated with COVID-19" exact="infection" post="along with prominent respiratory disease including pneumonia. Extensive research"/>
 <result pre="hepatic complications, are associated with COVID-19 infection along with prominent" exact="respiratory" post="disease including pneumonia. Extensive research work on recently discovered"/>
 <result pre="complications, are associated with COVID-19 infection along with prominent respiratory" exact="disease" post="including pneumonia. Extensive research work on recently discovered SARS-CoV-2"/>
 <result pre="from recovered COVID-19 patients to infected COVID-19 patients reduces the" exact="viral" post="burden via immunomodulation. This review analysis therefore concentrates primarily"/>
 <result pre="along with a full description of the structure, genome, and" exact="secondary" post="complication associated with SARS-CoV-2. Finally, a short and brief"/>
 <result pre="structure, genome, and secondary complication associated with SARS-CoV-2. Finally, a" exact="short" post="and brief clinical update has been provided concerning the"/>
 <result pre="to counter COVID-19. Graphical abstract Highlights â€¢COVID-19 is an emerging" exact="viral" post="pandemic with no specific clinical treatment available. â€¢COVID-19 induces"/>
 <result pre="immunomodulatory effect of convalescent plasma helps in reducing the SARS-CoV-2" exact="viral" post="load. Abbreviations ARI, acute renal injury ANG-I, angiotensin I"/>
 <result pre="plasma helps in reducing the SARS-CoV-2 viral load. Abbreviations ARI," exact="acute" post="renal injury ANG-I, angiotensin I ANG-II, angiotensin II ACE-2,"/>
 <result pre="angiotensin I ANG-II, angiotensin II ACE-2, angiotensin-converting enzyme 2 CRI," exact="chronic" post="renal injury CVD, cardiovascular diseases CTD, C-terminal domain ERGIC,"/>
 <result pre="II ACE-2, angiotensin-converting enzyme 2 CRI, chronic renal injury CVD," exact="cardiovascular" post="diseases CTD, C-terminal domain ERGIC, endoplasmic reticulum-golgi intermediate compartment"/>
 <result pre="injury CVD, cardiovascular diseases CTD, C-terminal domain ERGIC, endoplasmic reticulum-golgi" exact="intermediate" post="compartment NTD, N-terminal domain MERS-CoV, middle east respiratory syndrome"/>
 <result pre="endoplasmic reticulum-golgi intermediate compartment NTD, N-terminal domain MERS-CoV, middle east" exact="respiratory" post="syndrome coronavirus RBD, receptor-binding domain SARS-CoV, severe acute respiratory"/>
 <result pre="reticulum-golgi intermediate compartment NTD, N-terminal domain MERS-CoV, middle east respiratory" exact="syndrome" post="coronavirus RBD, receptor-binding domain SARS-CoV, severe acute respiratory syndrome"/>
 <result pre="middle east respiratory syndrome coronavirus RBD, receptor-binding domain SARS-CoV, severe" exact="acute" post="respiratory syndrome coronavirus SARS-CoV-2, severe acute respiratory syndrome coronavirus"/>
 <result pre="east respiratory syndrome coronavirus RBD, receptor-binding domain SARS-CoV, severe acute" exact="respiratory" post="syndrome coronavirus SARS-CoV-2, severe acute respiratory syndrome coronavirus 2"/>
 <result pre="respiratory syndrome coronavirus RBD, receptor-binding domain SARS-CoV, severe acute respiratory" exact="syndrome" post="coronavirus SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 TMPRSS,"/>
 <result pre="receptor-binding domain SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 TMPRSS, transmembrane protease serine protease-2"/>
 <result pre="domain SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 TMPRSS, transmembrane protease serine protease-2 (TMPRSS-2)"/>
 <result pre="SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 TMPRSS, transmembrane protease serine protease-2 (TMPRSS-2) 5â€™-UTR,"/>
 <result pre="Vaccines 1 Introduction According to the World Health Organization (WHO)," exact="viral" post="infections are widespread infectious diseases that cause serious public"/>
 <result pre="1 Introduction According to the World Health Organization (WHO), viral" exact="infections" post="are widespread infectious diseases that cause serious public health"/>
 <result pre="to the World Health Organization (WHO), viral infections are widespread" exact="infectious diseases" post="that cause serious public health concerns, resulting in thousands"/>
 <result pre="coronaviruses (CoVs) since the beginning of this century, i.e. severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002, middle-east respiratory syndrome"/>
 <result pre="(CoVs) since the beginning of this century, i.e. severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002, middle-east respiratory syndrome coronavirus"/>
 <result pre="since the beginning of this century, i.e. severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002, middle-east respiratory syndrome coronavirus (MERS-CoV)"/>
 <result pre="i.e. severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, middle-east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012, followed by the recent"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, middle-east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012, followed by the recent ongoing"/>
 <result pre="coronavirus (MERS-CoV) in 2012, followed by the recent ongoing severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. [2,3]. Numerous"/>
 <result pre="(MERS-CoV) in 2012, followed by the recent ongoing severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) in 2019. [2,3]. Numerous patients"/>
 <result pre="in 2012, followed by the recent ongoing severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) in 2019. [2,3]. Numerous patients with"/>
 <result pre="coronavirus 2 (SARS-CoV-2) in 2019. [2,3]. Numerous patients with baffling" exact="pneumonia" post="secondary to an unknown virus emerged in Wuhan, China"/>
 <result pre="2 (SARS-CoV-2) in 2019. [2,3]. Numerous patients with baffling pneumonia" exact="secondary" post="to an unknown virus emerged in Wuhan, China in"/>
 <result pre="as a new beta coronavirus and officially recognized as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [4,5]. On 11th February"/>
 <result pre="a new beta coronavirus and officially recognized as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [4,5]. On 11th February 2020,"/>
 <result pre="new beta coronavirus and officially recognized as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [4,5]. On 11th February 2020, the"/>
 <result pre="(SARS-CoV-2) [4,5]. On 11th February 2020, the WHO named this" exact="disease" post="as â€œCOVID-19,â€� and subsequently, on 11th March 2020, the"/>
 <result pre="million confirmed cases, 0.5 million confirmed deaths, and 5 million" exact="total" post="worldwide recoveries as of 30th June 2020. Numerous pieces"/>
 <result pre="[9]]. The clinical symptoms of COVID-19 vary from asymptomatic or" exact="symptomatic" post="to clinical conditions marked by respiratory distress to systemic"/>
 <result pre="vary from asymptomatic or symptomatic to clinical conditions marked by" exact="respiratory" post="distress to systemic effects of sepsis, shock, and multiple"/>
 <result pre="or symptomatic to clinical conditions marked by respiratory distress to" exact="systemic" post="effects of sepsis, shock, and multiple syndromes of organ"/>
 <result pre="older men with underlying diseases. Significant cases may involve dyspnea," exact="acute" post="respiratory distress syndrome, acute heart injury, acute kidney injury,"/>
 <result pre="men with underlying diseases. Significant cases may involve dyspnea, acute" exact="respiratory" post="distress syndrome, acute heart injury, acute kidney injury, acute"/>
 <result pre="diseases. Significant cases may involve dyspnea, acute respiratory distress syndrome," exact="acute" post="heart injury, acute kidney injury, acute liver injury, neurological"/>
 <result pre="Significant cases may involve dyspnea, acute respiratory distress syndrome, acute" exact="heart" post="injury, acute kidney injury, acute liver injury, neurological injury,"/>
 <result pre="may involve dyspnea, acute respiratory distress syndrome, acute heart injury," exact="acute" post="kidney injury, acute liver injury, neurological injury, gastrointestinal injury,"/>
 <result pre="involve dyspnea, acute respiratory distress syndrome, acute heart injury, acute" exact="kidney injury," post="acute liver injury, neurological injury, gastrointestinal injury, immune failure,"/>
 <result pre="acute respiratory distress syndrome, acute heart injury, acute kidney injury," exact="acute" post="liver injury, neurological injury, gastrointestinal injury, immune failure, compromised"/>
 <result pre="microscope due to the existence of spike-like glycoproteins on the" exact="viral" post="envelope [6]. SARS-CoV-2 belongs to Î²-coronavirus category, which contains"/>
 <result pre="human cell [15]. This receptor (ACE-2) is widely expressed in" exact="pulmonary" post="tissues as well as in some immune cells, including"/>
 <result pre="and trans-signaling in endothelial cells [[17], [18], [19], [20]]. SARS-CoV-2" exact="infection" post="cause final release and increase in pro-inflammatory cytokines, including"/>
 <result pre="cytokines, including interleukins, TNF-Î±, GCSF, and MCP [21,22]. This augmented" exact="systemic" post="cytokine storm seen in SARS-CoV-2 diagnosed patients underwrites the"/>
 <result pre="TNFSF10, CXCL10, IL10, TIMP1, C5, IL18, AREG and NRG1 in" exact="peripheral" post="mononuclear cells (PBMC) were induced by SARS-CoV-2; suggesting a"/>
 <result pre="health conditions will experience more severe illness characterized by substantial" exact="respiratory" post="symptoms leading to acute respiratory distress syndrome (ARDS) and"/>
 <result pre="more severe illness characterized by substantial respiratory symptoms leading to" exact="acute" post="respiratory distress syndrome (ARDS) and even death. Several epidemiological,"/>
 <result pre="severe illness characterized by substantial respiratory symptoms leading to acute" exact="respiratory" post="distress syndrome (ARDS) and even death. Several epidemiological, genetic,"/>
 <result pre="characterized by substantial respiratory symptoms leading to acute respiratory distress" exact="syndrome" post="(ARDS) and even death. Several epidemiological, genetic, and clinical"/>
 <result pre="even death. Several epidemiological, genetic, and clinical elements of COVID-19" exact="infection" post="resemble previous SARS-CoV and MERS-CoV infection [23]. Ironically, even"/>
 <result pre="clinical elements of COVID-19 infection resemble previous SARS-CoV and MERS-CoV" exact="infection" post="[23]. Ironically, even after the frequent re-emergence of CoVs"/>
 <result pre="infection [23]. Ironically, even after the frequent re-emergence of CoVs" exact="infections" post="and after several years of research, we still lack"/>
 <result pre="COVID-19 infection. Besides, a brief dialogue has been made on" exact="secondary" post="complications associated with COVID-19. Lastly, we have reviewed current"/>
 <result pre="cross-species transmission of this virus. First, there might be an" exact="intermediate" post="host between bats and humans. Most likely, it is"/>
 <result pre="genes, such as ORF3b and OFR8 [27]. Almost two-third of" exact="viral" post="RNA houses the first ORFs (ORF1a/b), which are further"/>
 <result pre="SARS-Cov-2. The ~1200 aa long glycoprotein spikes are homo-trimeric type-I" exact="viral" post="fusion proteins, which is vital to establish the host"/>
 <result pre="strands in the core, there is an extended insertion containing" exact="short" post="Î²5 and Î²6 strands, Î±4 and Î±5 helices and"/>
 <result pre="Fusion peptide (FP), Internal Fusion peptide (IFP), Heptad repeats (HR)," exact="Central" post="helix (CH), Connector domain (CD) and Cytoplasmic tail (CT)."/>
 <result pre="cells. The M protein provides a distinct shape to the" exact="viral" post="envelope by interacting with the nucleocapsid and by specific"/>
 <result pre="interacting with the nucleocapsid and by specific packaging of the" exact="viral" post="genome into the virion. Generally, M proteins in different"/>
 <result pre="of virion particles, and augmenting the transcription process of the" exact="viral" post="genome. N protein is also made up of three"/>
 <result pre="variable NTD interacts electrostatically with the 3â€² end of the" exact="viral" post="RNA. Similarly, the serine and arginine-rich LKR region also"/>
 <result pre="Similarly, the serine and arginine-rich LKR region also interacts with" exact="viral" post="RNA in vitro. However, its main role is in"/>
 <result pre="to the ACE-2 receptor, followed by the fusion of the" exact="viral" post="membrane with the host cell membrane. S-proteins are activated"/>
 <result pre="to attenuate the innate immune responses, especially the activation of" exact="type 1" post="interferon in host cells, ultimately leading to an enhanced"/>
 <result pre="as endoribonuclease EndoU) is vital for restraining the detection of" exact="viral" post="RNA by specific cytoplasmic pattern recognition receptors [30]. The"/>
 <result pre="fusion with the host cell membrane and then insertion of" exact="viral" post="RNA [32]. The S2 is made up of the"/>
 <result pre="suggests the high pathogenicity of this virus in the human" exact="respiratory" post="system [34,35]. Gene expression studies have shown that ACE2"/>
 <result pre="expression studies have shown that ACE2 occurs primarily in alveolar" exact="epithelial" post="type II cells of lungs, heart, kidney, adipose tissue,"/>
 <result pre="studies have shown that ACE2 occurs primarily in alveolar epithelial" exact="type II" post="cells of lungs, heart, kidney, adipose tissue, and nasal"/>
 <result pre="II cells of lungs, heart, kidney, adipose tissue, and nasal" exact="epithelial" post="cells (specifically in goblet cells and ciliated cells). Studies"/>
 <result pre="receptor complex interface with ACE2 [26]. After the fusion of" exact="viral" post="lipid bilayer through the endosomal pathway, SARS-Cov-2 injects its"/>
 <result pre="mRNAs by the discontinuous transcription, which gets translated into related" exact="viral" post="proteins [[17], [18], [19], [20]]. These viral particles are"/>
 <result pre="translated into related viral proteins [[17], [18], [19], [20]]. These" exact="viral" post="particles are processed futher into the endoplasmic reticulum-golgi intermediate"/>
 <result pre="These viral particles are processed futher into the endoplasmic reticulum-golgi" exact="intermediate" post="compartment (ERGIC). Here, nsps play an essential role by"/>
 <result pre="membranes coming from the ERGIC into the double-membrane vesicles, where" exact="viral" post="replication and transcription occur [[17], [18], [19], [20]]. Subsequently,"/>
 <result pre="[20]]. Subsequently, the nucleocapsid is produced by the aggregation of" exact="viral" post="RNA and nucleocapsid protein. At last, the virion particles"/>
 <result pre="exocytosis or extrusion [32]. (Fig. 3 ). Fig. 3 The" exact="complete" post="life cycle of SARS-Cov-2 inside the host cell. ACE2:"/>
 <result pre="SER: Smooth Endoplasmic reticulum, GC: Golgi apparatus. 4 COVID-19 and" exact="secondary" post="manifestations: recent update 4.1 Impact of COVID-19 on cardiovascular"/>
 <result pre="and secondary manifestations: recent update 4.1 Impact of COVID-19 on" exact="cardiovascular" post="system COVs such as SARS, MERS, and COVID-19, have"/>
 <result pre="and COVID-19, have mainly been associated with the number of" exact="cardiovascular" post="complications such as myocarditis, myocardial injury, cardiac shock, cardiac"/>
 <result pre="of cardiovascular complications such as myocarditis, myocardial injury, cardiac shock," exact="cardiac arrhythmia," post="heart failure [37]. Although. the dominant clinical feature of"/>
 <result pre="complications such as myocarditis, myocardial injury, cardiac shock, cardiac arrhythmia," exact="heart" post="failure [37]. Although. the dominant clinical feature of COVID-19"/>
 <result pre="the dominant clinical feature of COVID-19 is considered to be" exact="respiratory" post="dysfunction, but some patients showed severe damage to the"/>
 <result pre="respiratory dysfunction, but some patients showed severe damage to the" exact="cardiovascular" post="system. Recent reports suggested that patients with cardiovascular diseases"/>
 <result pre="to the cardiovascular system. Recent reports suggested that patients with" exact="cardiovascular" post="diseases (CVD) have been at increased risk of death"/>
 <result pre="patients showed that out of 121 patients, 12 patients had" exact="cardiovascular" post="complications with tachycardia and hypotension were the most common"/>
 <result pre="finding reported besides with the other complications such as bradycardia," exact="transient" post="cardiomegaly [40]. In line with SARS, the latest case"/>
 <result pre="reported besides with the other complications such as bradycardia, transient" exact="cardiomegaly" post="[40]. In line with SARS, the latest case reports"/>
 <result pre="50% of patients with a high risk of mortality have" exact="chronic" post="CVD. Recently, the clinical report of COVID-19 revealed that"/>
 <result pre="COVID-19 revealed that 7.2%, 8.7%, and 16.7% of patients with" exact="acute" post="cardiac injury, shock, and arrhythmia, respectively, required immediate hospitalization"/>
 <result pre="CDC showed that 25% of patients have pre-existing comorbidities like" exact="cardiovascular" post="complications and diabetes [41]. A case report on 138"/>
 <result pre="25% of patients have pre-existing comorbidities like cardiovascular complications and" exact="diabetes" post="[41]. A case report on 138 COVID-19 patients reported"/>
 <result pre="that 19.6%, 16.7%, 7.2%, 8.7%, and 3.6% of patients developed" exact="acute" post="respiratory distress syndrome, arrhythmia, acute cardiac injury, shock, and"/>
 <result pre="19.6%, 16.7%, 7.2%, 8.7%, and 3.6% of patients developed acute" exact="respiratory" post="distress syndrome, arrhythmia, acute cardiac injury, shock, and acute"/>
 <result pre="and 3.6% of patients developed acute respiratory distress syndrome, arrhythmia," exact="acute" post="cardiac injury, shock, and acute kidney injury, respectively [[7],"/>
 <result pre="acute respiratory distress syndrome, arrhythmia, acute cardiac injury, shock, and" exact="acute" post="kidney injury, respectively [[7], [8], [9]] (Fig. 4 )."/>
 <result pre="respiratory distress syndrome, arrhythmia, acute cardiac injury, shock, and acute" exact="kidney injury," post="respectively [[7], [8], [9]] (Fig. 4 ). The overall"/>
 <result pre="for CVD (10.5%) is bigger as compared to patients with" exact="chronic" post="respiratory disease (6.3%) [41]. Fig. 4 Summary of secondary"/>
 <result pre="CVD (10.5%) is bigger as compared to patients with chronic" exact="respiratory" post="disease (6.3%) [41]. Fig. 4 Summary of secondary complications"/>
 <result pre="(10.5%) is bigger as compared to patients with chronic respiratory" exact="disease" post="(6.3%) [41]. Fig. 4 Summary of secondary complications associated"/>
 <result pre="with chronic respiratory disease (6.3%) [41]. Fig. 4 Summary of" exact="secondary" post="complications associated with COVID-19 infection. CVD may become more"/>
 <result pre="infection. CVD may become more severe in the presence of" exact="viral infection" post="because of the imbalance between the increased metabolic demand"/>
 <result pre="CVD may become more severe in the presence of viral" exact="infection" post="because of the imbalance between the increased metabolic demand"/>
 <result pre="increased metabolic demand and reduced cardiac reserve. Therefore, patients with" exact="coronary artery disease" post="and heart failure have a high mortality rate [42]."/>
 <result pre="metabolic demand and reduced cardiac reserve. Therefore, patients with coronary" exact="artery disease" post="and heart failure have a high mortality rate [42]."/>
 <result pre="demand and reduced cardiac reserve. Therefore, patients with coronary artery" exact="disease" post="and heart failure have a high mortality rate [42]."/>
 <result pre="and reduced cardiac reserve. Therefore, patients with coronary artery disease" exact="and heart" post="failure have a high mortality rate [42]. ACE-2 was"/>
 <result pre="reduced cardiac reserve. Therefore, patients with coronary artery disease and" exact="heart" post="failure have a high mortality rate [42]. ACE-2 was"/>
 <result pre="by ACE. ANG II then unites to the ANG II" exact="type 1" post="receptor (AT1R) to promote inflammation, oxidative stress, and increase"/>
 <result pre="that over-expression of ACE2 can prevent or even reverse the" exact="heart" post="failure phenotype, whereas loss of ACE2 can enhance the"/>
 <result pre="phenotype, whereas loss of ACE2 can enhance the progression of" exact="heart" post="failure [45,46]. Various research groups have documented that SARS-CoV-2"/>
 <result pre="as a cellular entry receptor [15,39] and the degree of" exact="infection" post="caused by SARS-CoV-2 in heart or other cardiovascular tissues"/>
 <result pre="[15,39] and the degree of infection caused by SARS-CoV-2 in" exact="heart" post="or other cardiovascular tissues (potentially contributes to the myocarditis)"/>
 <result pre="degree of infection caused by SARS-CoV-2 in heart or other" exact="cardiovascular" post="tissues (potentially contributes to the myocarditis) is largely unknown."/>
 <result pre="myocarditis) is largely unknown. Therefore, it can be concluded that" exact="cardiovascular" post="tissues or cells expressing ACE2 are possibly at extreme"/>
 <result pre="and maybe long term [43,44]. 4.2 COVID-19 and neurological complications" exact="Viral" post="contamination can lead to origin of serious damage to"/>
 <result pre="contamination can lead to origin of serious damage to the" exact="brain" post="and spinal cord, including encephalitis and severe acute demyelinating"/>
 <result pre="of serious damage to the brain and spinal cord, including" exact="encephalitis" post="and severe acute demyelinating lesions [47,48]. A recent study"/>
 <result pre="to the brain and spinal cord, including encephalitis and severe" exact="acute" post="demyelinating lesions [47,48]. A recent study (nÂ =Â 214)"/>
 <result pre="the brain and spinal cord, including encephalitis and severe acute" exact="demyelinating" post="lesions [47,48]. A recent study (nÂ =Â 214) concluded"/>
 <result pre="recent study (nÂ =Â 214) concluded that, in addition to" exact="systemic" post="and respiratory symptoms, 36.4% (78/214) of total COVID-19 patients"/>
 <result pre="(nÂ =Â 214) concluded that, in addition to systemic and" exact="respiratory" post="symptoms, 36.4% (78/214) of total COVID-19 patients develop neurological"/>
 <result pre="in addition to systemic and respiratory symptoms, 36.4% (78/214) of" exact="total" post="COVID-19 patients develop neurological symptoms [49]. Recently reports from"/>
 <result pre="restlessness loss of smell (anosmia), and taste (dysgeusia) due to" exact="infection" post="in the brain [[17], [18], [19], [20]]. The neurological"/>
 <result pre="smell (anosmia), and taste (dysgeusia) due to infection in the" exact="brain" post="[[17], [18], [19], [20]]. The neurological symptoms of COVID-19"/>
 <result pre="severe (hypo-ageusia, hyposmia, neuralgia) [[17], [18], [19], [20]] (Fig. 4)." exact="Encephalopathy" post="is one of the prominent symptoms of viral infection,"/>
 <result pre="(Fig. 4). Encephalopathy is one of the prominent symptoms of" exact="viral infection," post="and several reports published that encephalopathy has been seen"/>
 <result pre="prominent symptoms of viral infection, and several reports published that" exact="encephalopathy" post="has been seen in patients with COVID-19 as proof"/>
 <result pre="has been seen in patients with COVID-19 as proof of" exact="brain" post="infection due to this SARS-CoV-2 [[17], [18], [19], [20]]."/>
 <result pre="been seen in patients with COVID-19 as proof of brain" exact="infection" post="due to this SARS-CoV-2 [[17], [18], [19], [20]]. Still,"/>
 <result pre="there is a question for scientists or neurologist that the" exact="brain" post="infection due to COVID-19 play a role in respiratory"/>
 <result pre="is a question for scientists or neurologist that the brain" exact="infection" post="due to COVID-19 play a role in respiratory trouble"/>
 <result pre="the brain infection due to COVID-19 play a role in" exact="respiratory" post="trouble or vice versa and this regard one report"/>
 <result pre="al. [[17], [18], [19], [20]] suggested that COVID-19 might infect" exact="respiratory" post="center located in the medulla oblongata and pons (brainstem)"/>
 <result pre="similarities between SARS-CoV and COVID-19 for following the pathway of" exact="infection" post="[[17], [18], [19], [20]]. Guillain-Barre syndrome (GBS) associated with"/>
 <result pre="for following the pathway of infection [[17], [18], [19], [20]]." exact="Guillain-Barre syndrome" post="(GBS) associated with COVID-19 was firstly reported in China"/>
 <result pre="following the pathway of infection [[17], [18], [19], [20]]. Guillain-Barre" exact="syndrome" post="(GBS) associated with COVID-19 was firstly reported in China"/>
 <result pre="that SARS-CoV-2 has been found in CSF and can infect" exact="brain" post="cells and subsequently cause viral encephalitis [47,48,50]. Moreover, another"/>
 <result pre="in CSF and can infect brain cells and subsequently cause" exact="viral encephalitis" post="[47,48,50]. Moreover, another study reported that out of 221"/>
 <result pre="CSF and can infect brain cells and subsequently cause viral" exact="encephalitis" post="[47,48,50]. Moreover, another study reported that out of 221"/>
 <result pre="COVID-19 patients in Wuhan, China, 11 patients have established stroke," exact="cerebral thrombosis," post="and cerebral hemorrhage. If we look back at previously"/>
 <result pre="Wuhan, China, 11 patients have established stroke, cerebral thrombosis, and" exact="cerebral hemorrhage." post="If we look back at previously published reports in"/>
 <result pre="were administered in mice through nasal routes, which enter the" exact="brain" post="through olfactory nerves and spread throughout the brain. Various"/>
 <result pre="reported for SARS-CoV-2 induced CNS damage including entry into the" exact="brain" post="through blood circulation, by infecting the sensory and motor"/>
 <result pre="brain through blood circulation, by infecting the sensory and motor" exact="nerve" post="endings and some indirect mechanisms like hypoxia or loss"/>
 <result pre="sensory and motor nerve endings and some indirect mechanisms like" exact="hypoxia" post="or loss of oxygen also cause decrease supply of"/>
 <result pre="loss of oxygen also cause decrease supply of oxygen in" exact="brain" post="tissue cause acute or permanent changes in the brain"/>
 <result pre="also cause decrease supply of oxygen in brain tissue cause" exact="acute" post="or permanent changes in the brain areas [47,48]. Viruses"/>
 <result pre="in brain tissue cause acute or permanent changes in the" exact="brain" post="areas [47,48]. Viruses may penetrate the brain and exacerbate"/>
 <result pre="changes in the brain areas [47,48]. Viruses may penetrate the" exact="brain" post="and exacerbate infections by activating neuroinflammation. i.e. excessive activation"/>
 <result pre="brain areas [47,48]. Viruses may penetrate the brain and exacerbate" exact="infections" post="by activating neuroinflammation. i.e. excessive activation and release of"/>
 <result pre="for a deep understanding of the possible link between the" exact="brain" post="and respiratory infection by COVID-19, and clinical reports or"/>
 <result pre="deep understanding of the possible link between the brain and" exact="respiratory" post="infection by COVID-19, and clinical reports or biopsy studies"/>
 <result pre="understanding of the possible link between the brain and respiratory" exact="infection" post="by COVID-19, and clinical reports or biopsy studies may"/>
 <result pre="COVID-19, and clinical reports or biopsy studies may conclude that" exact="brain" post="infection involved or not in respiratory failure. 4.3 Impact"/>
 <result pre="and clinical reports or biopsy studies may conclude that brain" exact="infection" post="involved or not in respiratory failure. 4.3 Impact of"/>
 <result pre="studies may conclude that brain infection involved or not in" exact="respiratory" post="failure. 4.3 Impact of COVID-19 on renal system Several"/>
 <result pre="system Several published studies on COVID-19 enlightened lungs and the" exact="respiratory" post="system as the principal organ/system involved and affected in"/>
 <result pre="involved and affected in the disease; meanwhile, manifestations of this" exact="disease" post="also involves other organs like the gastrointestinal tract, renal"/>
 <result pre="are already suffering from hepatic disorders, GIT disorders, ARI (Acute" exact="Renal" post="Injury) or CRI (Chronic Renal Injury) and thus results"/>
 <result pre="disorders, GIT disorders, ARI (Acute Renal Injury) or CRI (Chronic" exact="Renal" post="Injury) and thus results in higher mortality rate [[17],"/>
 <result pre="ARI and liver dysfunction are the main complications, along with" exact="acute" post="respiratory distress syndrome, arrhythmia, acute cardiac injury, shock, and"/>
 <result pre="and liver dysfunction are the main complications, along with acute" exact="respiratory" post="distress syndrome, arrhythmia, acute cardiac injury, shock, and other"/>
 <result pre="the main complications, along with acute respiratory distress syndrome, arrhythmia," exact="acute" post="cardiac injury, shock, and other secondary infections. Studies also"/>
 <result pre="respiratory distress syndrome, arrhythmia, acute cardiac injury, shock, and other" exact="secondary" post="infections. Studies also revealed that ARI is one of"/>
 <result pre="Previously published reports during the outbreak of SARS and MERS-CoV" exact="infections" post="claim that ARI was observed in 15% cases with"/>
 <result pre="patients with COVID-19, between January to February 2020 including 28" exact="pneumonia" post="patients (15 viral pneumonia and 13 mycoplasma pneumonia patients)"/>
 <result pre="between January to February 2020 including 28 pneumonia patients (15" exact="viral pneumonia" post="and 13 mycoplasma pneumonia patients) concluded that proteinuria was"/>
 <result pre="January to February 2020 including 28 pneumonia patients (15 viral" exact="pneumonia" post="and 13 mycoplasma pneumonia patients) concluded that proteinuria was"/>
 <result pre="including 28 pneumonia patients (15 viral pneumonia and 13 mycoplasma" exact="pneumonia" post="patients) concluded that proteinuria was observed in 59% cases,"/>
 <result pre="pneumonia patients) concluded that proteinuria was observed in 59% cases," exact="hematuria" post="in 44%, elevated levels of blood urea nitrogen in"/>
 <result pre="cases, which is significantly worse as compared to the other" exact="pneumonia" post="cases (Fig. 4). A univariate Cox regression analysis was"/>
 <result pre="without ARI and even much higher than those with comorbid" exact="chronic" post="illnesses [[17], [18], [19], [20]]. Similarly, another study was"/>
 <result pre="age of 63Â years. The study concluded that proteinuria and" exact="hematuria" post="were found in 43.9% and 26.7% patients, respectively, whereas"/>
 <result pre="with high in-hospital mortality [53]. The etiology or pathogenesis of" exact="kidney injury" post="in patients with COVID-19 is not precisely clear but"/>
 <result pre="[[17], [18], [19], [20]]. Hence, we can conclude that the" exact="renal failure" post="might be raised due to coronavirus entering in the"/>
 <result pre="of renal impairment may be due to hypoxia, shock, and" exact="rhabdomyolysis" post="exerted by cytokine storm. Also, dehydration resulting from fever"/>
 <result pre="in case of mild to moderate fluid depletion. However, if" exact="ischemia" post="persists, then acute tubular necrosis may occur. These pathways"/>
 <result pre="mild to moderate fluid depletion. However, if ischemia persists, then" exact="acute" post="tubular necrosis may occur. These pathways are expected to"/>
 <result pre="other pathways responsible for renal impairment in COVID-19 patients [56]." exact="Renal" post="impairment in COVID-19 (Coronavirus induced-nephropathy) has a complicated and"/>
 <result pre="with COVID-19 with caution is necessary irrespective of the past" exact="disease" post="history, so that early clinical interventions could be taken"/>
 <result pre="pathogens. In 2003, during the SARS outbreak, SARS-CoV reportedly caused" exact="atypical pneumonia" post="and served as a contributing factor in liver impairment"/>
 <result pre="In 2003, during the SARS outbreak, SARS-CoV reportedly caused atypical" exact="pneumonia" post="and served as a contributing factor in liver impairment"/>
 <result pre="the patients [59,60]. It has been reported that the severity" exact="of liver" post="damage was directly proportional to the severity of cases"/>
 <result pre="cellular entry of SARS-CoV [13]. Significant increase in mitotic cells," exact="eosinophilic" post="debris and balloon-like hepatocytes has been shown in the"/>
 <result pre="mildly elevated bilirubin levels during the initial stages of the" exact="disease" post="(Fig. 4). The possibility of developing liver injury mainly"/>
 <result pre="of developing liver injury mainly depends upon the severity of" exact="disease" post="in COVID-19 patients, more severe the patient, higher the"/>
 <result pre="in COVID-19 patients, more severe the patient, higher the possibility" exact="of liver" post="injury and vice-versa [37,65]. It has been found that"/>
 <result pre="bile duct is significantly higher as compared to endothelial cells" exact="of liver" post="cells. These results from various studies suggested that damage"/>
 <result pre="for liver impairment in COVID-19 patients, along with the damage" exact="of liver" post="cells. Excessive inflammatory cytokines have been observed in endothelial"/>
 <result pre="a moderate level of microvascular steatosis indicates that either SARS-CoV-2" exact="infection" post="or drug used during treatment was the possible cause"/>
 <result pre="and nausea, before showing signs and symptoms of fever and" exact="lower" post="respiratory tract. A meta-analysis of COVID-19 patients (nÂ =Â"/>
 <result pre="nausea, before showing signs and symptoms of fever and lower" exact="respiratory" post="tract. A meta-analysis of COVID-19 patients (nÂ =Â 4243)"/>
 <result pre="Appetite loss (26.8%) was the most common symptom, accompanied by" exact="diarrhea" post="(12.5%), nausea/vomiting (10.2%), and stomach pain/discomfort (9.2%) [11,70]. SARS-CoV-2"/>
 <result pre="patients without any GI symptoms. In addition, patients with presenting" exact="diarrhea" post="had higher stool RNA presence and viral load than"/>
 <result pre="patients with presenting diarrhea had higher stool RNA presence and" exact="viral" post="load than patients with no diarrhea. Due to 80%"/>
 <result pre="diarrhea. Due to 80% similarity to SARS-CoV, SARS-CoV-2 persuaded GIT" exact="infection" post="is not surprising and is specified to be mediated"/>
 <result pre="binding affinity of ACE2 receptors determines infectivity. Since ACE2 modulates" exact="bowel" post="inflammation, SARS-CoV-2 can disrupt ACE2 â€˜s function and lead"/>
 <result pre="inflammation, SARS-CoV-2 can disrupt ACE2 â€˜s function and lead to" exact="diarrhea" post="[70]. Because of the similarity of SARS and COVID-19"/>
 <result pre="a double edge sword for the population suffering from diabetes." exact="Diabetes" post="is a significant risk factor for hospitalization and mortality"/>
 <result pre="well established that diabetic population is at high-risk group for" exact="viral infection" post="due to hyperglycemia-induced increased oxidative stress as well as"/>
 <result pre="established that diabetic population is at high-risk group for viral" exact="infection" post="due to hyperglycemia-induced increased oxidative stress as well as"/>
 <result pre="mortality and morbidity in COVID-19 patients with diabetes. Most notably," exact="diabetes" post="was too considered as a risk factor during previous"/>
 <result pre="MERS and severe influenza A H1N1 pandemic [[72], [73], [74]]." exact="Infection" post="of SARS-CoV-2 in diabetic patientâ€™ perhaps trigger the excess"/>
 <result pre="a retrospective study conducted in the first epicenter of COVID-19" exact="infection" post="(Wuhan) confirmed that about 10% of the COVID-19 patients"/>
 <result pre="COVID-19 patients with T2DM suffered at least one episode of" exact="hypoglycemia" post="[75]. Moreover, a recently published meta-analysis of 12 studies"/>
 <result pre="from 2108 Chinese COVID-19 patients concluded that the prevalence of" exact="diabetes" post="in COVID-19 patients is 10.3%, which is similar to"/>
 <result pre="population [76]. Therefore, it can be concluded that though pre-existing" exact="diabetes" post="worsens the consequences in COVID-19 patients, but the predisposition"/>
 <result pre="patients, but the predisposition of the diabetic population to SARS-CoV-2" exact="infection" post="may not be higher as compared to healthy people."/>
 <result pre="healthy people. A previous study of SARS-CoV patients without pre-existing" exact="diabetes" post="(nÂ =Â 39) has reported that 20 of the"/>
 <result pre="has reported that 20 of the 39 SARS-CoV patients developed" exact="diabetes" post="during hospitalization because immunostaining of ACE-2 in the pancreatic"/>
 <result pre="suggested that SARS-CoV might have damaged pancreatic islets and caused" exact="acute" post="Type I diabetes mellitus like condition [74,76]. Whereas in"/>
 <result pre="that SARS-CoV might have damaged pancreatic islets and caused acute" exact="Type I" post="diabetes mellitus like condition [74,76]. Whereas in the case"/>
 <result pre="might have damaged pancreatic islets and caused acute Type I" exact="diabetes mellitus" post="like condition [74,76]. Whereas in the case of SARS-COV-2,"/>
 <result pre="that pancreatic destruction in COVID-19 patients. The development of a" exact="viral infection" post="in diabetic patients renders them harder to treat due"/>
 <result pre="pancreatic destruction in COVID-19 patients. The development of a viral" exact="infection" post="in diabetic patients renders them harder to treat due"/>
 <result pre="to oscillating blood glucose levels and the presence of other" exact="secondary" post="diabetic complications. Therefore, it can be hypothesized that the"/>
 <result pre="ACE-2 polymorphisms in Asian populations, which is further linked to" exact="diabetes mellitus" post="and hypertension, genetically predisposes towards increased risk of SARS-COV-2"/>
 <result pre="mellitus and hypertension, genetically predisposes towards increased risk of SARS-COV-2" exact="infection" post="[94]. In a nutshell, intake of ACE inhibitors may"/>
 <result pre="blood glucose ([77], https://diabetesvoice.org/en/news/covid-19-and-diabetes/). Pregnant females are exceptionally predisposed to" exact="viral" post="pathogens and pneumonia since a lot of physiologic alterations"/>
 <result pre="https://diabetesvoice.org/en/news/covid-19-and-diabetes/). Pregnant females are exceptionally predisposed to viral pathogens and" exact="pneumonia" post="since a lot of physiologic alterations takes place in"/>
 <result pre="gets elevated, oxygen demand increased, along with edema of the" exact="upper" post="respiratory tract), [78,93]. Earlier, viral pneumonia in pregnant women"/>
 <result pre="elevated, oxygen demand increased, along with edema of the upper" exact="respiratory" post="tract), [78,93]. Earlier, viral pneumonia in pregnant women was"/>
 <result pre="along with edema of the upper respiratory tract), [78,93]. Earlier," exact="viral pneumonia" post="in pregnant women was shown to be correlated with"/>
 <result pre="with edema of the upper respiratory tract), [78,93]. Earlier, viral" exact="pneumonia" post="in pregnant women was shown to be correlated with"/>
 <result pre="physiological adaptive changes render pregnant women more susceptible to COVID-19" exact="infection" post="than the general population [79]. In this context, a"/>
 <result pre="well as on their neonates in China. Despite having a" exact="limited" post="sample size, the study concluded zero cases of intrauterine"/>
 <result pre="clinical records of pregnant women (nÂ =Â 116) with COVID-19" exact="pneumonia" post="between January 20 and March 24, 2020. The median"/>
 <result pre="pneumonia between January 20 and March 24, 2020. The median" exact="gestational" post="age of all pregnant women was 36Â weeks, and"/>
 <result pre="that the observed clinical symptoms of pregnant women with COVID-19" exact="pneumonia" post="are identical to those of non-pregnant women with COVID-19"/>
 <result pre="pregnant women with COVID 19 are more susceptible to severe" exact="pneumonia" post="and vertical transmission of SARS-CoV-2 to fetus during the"/>
 <result pre="authors have concluded that in pregnant women infected with COVID-19," exact="diabetes" post="and hypertension are among the top associated comorbidities and"/>
 <result pre="concluded that in pregnant women infected with COVID-19, diabetes and" exact="hypertension" post="are among the top associated comorbidities and there is"/>
 <result pre="newborn child to COVID-19 mothers have displayed the occurrence of" exact="respiratory" post="distress syndrome as well as pneumonia and some proof"/>
 <result pre="to COVID-19 mothers have displayed the occurrence of respiratory distress" exact="syndrome" post="as well as pneumonia and some proof of vertical"/>
 <result pre="displayed the occurrence of respiratory distress syndrome as well as" exact="pneumonia" post="and some proof of vertical maternal-fetal transmission of SARS-CoV-2"/>
 <result pre="pneumonia and some proof of vertical maternal-fetal transmission of SARS-CoV-2" exact="infection" post="[81]. A recent study on pediatric patients with COVID-19"/>
 <result pre="This is suggestive of the fact that all ages in" exact="childhood" post="are equally susceptible to SARD-CoV-2 [82]. Moreover, the children's"/>
 <result pre="as compared to adults, children are expectedly more prone to" exact="upper" post="respiratory infections (for e.g., respiratory syncytial virus in winter),"/>
 <result pre="compared to adults, children are expectedly more prone to upper" exact="respiratory" post="infections (for e.g., respiratory syncytial virus in winter), and"/>
 <result pre="to adults, children are expectedly more prone to upper respiratory" exact="infections" post="(for e.g., respiratory syncytial virus in winter), and their"/>
 <result pre="are expectedly more prone to upper respiratory infections (for e.g.," exact="respiratory" post="syncytial virus in winter), and their blood might have"/>
 <result pre="andÂ 84]. Based on current evidences, CVD, hypertension, COPD, asthma," exact="diabetes mellitus," post="renal failure, hepatic disorder, cancer, and immunocompromised status are"/>
 <result pre="Based on current evidences, CVD, hypertension, COPD, asthma, diabetes mellitus," exact="renal failure," post="hepatic disorder, cancer, and immunocompromised status are some of"/>
 <result pre="current evidences, CVD, hypertension, COPD, asthma, diabetes mellitus, renal failure," exact="hepatic disorder," post="cancer, and immunocompromised status are some of the pre-existing"/>
 <result pre="or contain COVID-19. The on-going clinical management for COVID-19 includes" exact="disease" post="prevention (use of some clinically approved anti-viral drugs, hydroxychloroquine,"/>
 <result pre="rate ([86] issues emergency-use-authorization-potential-covid-19-treatment). In addition, Indian authorities (Drug Controller" exact="General" post="of India) have approved oral antiviral drug favipiravir to"/>
 <result pre="(sample size) Findings Status Clinical trial identifier 1. Hydroxychloroquine Block" exact="viral" post="entry by inhibiting glycosylation of host receptors, proteolytic processing,"/>
 <result pre="Result Posted for this study Completed NCT04358614 5. GanovoRitonavirInterferon nebulization" exact="Hepatitis" post="C virus protease inhibitor Phase IV(11) No Result Posted"/>
 <result pre="(CHiCTR2000029548) 2. Favipiravir Broad-spectrum antiviral drug which cause inhibition of" exact="viral" post="RNA-dependent RNA polymerase against various viruses, including coronaviruses Favipiravir"/>
 <result pre="antiretroviral drug of the protease inhibitor class used to treat" exact="HIV infection" post="National Clinical Trial Identifier:(NCT04307693), (NCT04276688), (NCT04328012) 4. Oseltamivir Anti-viral"/>
 <result pre="drug of the protease inhibitor class used to treat HIV" exact="infection" post="National Clinical Trial Identifier:(NCT04307693), (NCT04276688), (NCT04328012) 4. Oseltamivir Anti-viral"/>
 <result pre="as nucleotide analog, specifically an adenosine analogue, which inserts into" exact="viral" post="RNA chains, causing their premature termination. National Clinical Trial"/>
 <result pre="including coronaviruses Umifenovir is an antiviral treatment used for influenza" exact="infection" post="used in Russia and China. National Clinical Trial Identifier:(NCT04252885),"/>
 <result pre="(NCT04260594)Chinese Clinical Trial Registration Number:(ChiCTR200030254)    Supporting agents 7. Anakinra" exact="Disease" post="modifying Anti -rheumatic DrugRecombinant human interleukin-1 (IL-1) receptor antagonist;"/>
 <result pre="-rheumatic DrugRecombinant human interleukin-1 (IL-1) receptor antagonist; inhibit cytokine release" exact="syndrome" post="(CRS) symptoms or cytokine storm in severely ill patients"/>
 <result pre="ill patients Anakinra is clinically approved to manage symptoms of" exact="rheumatoid arthritis" post="National Clinical Trial Identifier:(NCT04324021), (NCT04356366), (NCT04339712), (NCT04330638) 8. Ascorbic"/>
 <result pre="patients Anakinra is clinically approved to manage symptoms of rheumatoid" exact="arthritis" post="National Clinical Trial Identifier:(NCT04324021), (NCT04356366), (NCT04339712), (NCT04330638) 8. Ascorbic"/>
 <result pre="cofactor for numerous physiologic reactions; may support host defenses against" exact="infection" post="and protect host cells against infection induced oxidative stress"/>
 <result pre="support host defenses against infection and protect host cells against" exact="infection" post="induced oxidative stress Ascorbic acid is clinically used to"/>
 <result pre="acid is clinically used to prevent and treat scurvy, a" exact="disease" post="caused by a lack of vitamin C National Clinical"/>
 <result pre="theoretically could contribute to an antiinflammatory response in patients with" exact="viral" post="infections Azithromycin is clinically used as adjunctive therapy to"/>
 <result pre="could contribute to an antiinflammatory response in patients with viral" exact="infections" post="Azithromycin is clinically used as adjunctive therapy to management"/>
 <result pre="is clinically used as adjunctive therapy to management of certain" exact="respiratory" post="conditions (e.g., bronchiectasis, bronchiolitis, cystic fibrosis, COPD exacerbations, ARDS)Hydroxychloroquine"/>
 <result pre="therapy to management of certain respiratory conditions (e.g., bronchiectasis, bronchiolitis," exact="cystic fibrosis," post="COPD exacerbations, ARDS)Hydroxychloroquine is also FDA-approved to treat malaria"/>
 <result pre="cystic fibrosis, COPD exacerbations, ARDS)Hydroxychloroquine is also FDA-approved to treat" exact="malaria" post="and autoimmune conditions such as chronic discoid lupus erythematosus,"/>
 <result pre="COPD exacerbations, ARDS)Hydroxychloroquine is also FDA-approved to treat malaria and" exact="autoimmune" post="conditions such as chronic discoid lupus erythematosus, systemic lupus"/>
 <result pre="also FDA-approved to treat malaria and autoimmune conditions such as" exact="chronic" post="discoid lupus erythematosus, systemic lupus erythematosus in adults, and"/>
 <result pre="to treat malaria and autoimmune conditions such as chronic discoid" exact="lupus erythematosus," post="systemic lupus erythematosus in adults, and rheumatoid arthritis National"/>
 <result pre="malaria and autoimmune conditions such as chronic discoid lupus erythematosus," exact="systemic" post="lupus erythematosus in adults, and rheumatoid arthritis National Clinical"/>
 <result pre="and autoimmune conditions such as chronic discoid lupus erythematosus, systemic" exact="lupus erythematosus" post="in adults, and rheumatoid arthritis National Clinical Trial Identifier:(NCT04329832),"/>
 <result pre="chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and" exact="rheumatoid arthritis" post="National Clinical Trial Identifier:(NCT04329832), (NCT04339426), (NCT04334382),(NCT04336332), (NCT04341870), (NCT04332094),(NCT04335552), (NCT04344379),"/>
 <result pre="discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid" exact="arthritis" post="National Clinical Trial Identifier:(NCT04329832), (NCT04339426), (NCT04334382),(NCT04336332), (NCT04341870), (NCT04332094),(NCT04335552), (NCT04344379),"/>
 <result pre="and chemokines Colchicine is clinically approved medication used to treat" exact="gout" post="and BehÃ§et's disease National Clinical Trial Identifier:(NCT04326790), (NCT04322565), (NCT04328480),"/>
 <result pre="is clinically approved medication used to treat gout and BehÃ§et's" exact="disease" post="National Clinical Trial Identifier:(NCT04326790), (NCT04322565), (NCT04328480), (NCT04350320), (NCT04355143) 11."/>
 <result pre="prevent an extended cytokine response and may accelerate resolution of" exact="pulmonary" post="and systemic inflammation in pneumonia, may combat cytokine storm"/>
 <result pre="extended cytokine response and may accelerate resolution of pulmonary and" exact="systemic" post="inflammation in pneumonia, may combat cytokine storm Corticosteroid drugs"/>
 <result pre="combat cytokine storm Corticosteroid drugs are clinically used to treat" exact="rheumatoid arthritis," post="lupus, asthma, allergies and many other inflammatory conditions National"/>
 <result pre="drugs are clinically used to treat rheumatoid arthritis, lupus, asthma," exact="allergies" post="and many other inflammatory conditions National Clinical Trial Identifier:(NCT04327401),"/>
 <result pre="conditions National Clinical Trial Identifier:(NCT04327401), (NCT04344730), (NCT04348305) 12. Nitric oxide" exact="Selective" post="pulmonary vasodilator; may be useful in the adjunctive treatment"/>
 <result pre="National Clinical Trial Identifier:(NCT04327401), (NCT04344730), (NCT04348305) 12. Nitric oxide Selective" exact="pulmonary" post="vasodilator; may be useful in the adjunctive treatment of"/>
 <result pre="pulmonary vasodilator; may be useful in the adjunctive treatment of" exact="acute" post="respiratory distress syndrome (ARDS), a potential complication of COVID-19"/>
 <result pre="vasodilator; may be useful in the adjunctive treatment of acute" exact="respiratory" post="distress syndrome (ARDS), a potential complication of COVID-19 National"/>
 <result pre="be useful in the adjunctive treatment of acute respiratory distress" exact="syndrome" post="(ARDS), a potential complication of COVID-19 National Clinical Trial"/>
 <result pre="1 and 2 inhibitor; 7 may potentially combat cytokine release" exact="syndrome" post="(CRS) in severely ill patientsAbility to inhibit a variety"/>
 <result pre="to inhibit a variety of proinflammatory cytokines, including interferon, during" exact="viral" post="infections such as COVID-19 Ruxolitinib is a clinically approved"/>
 <result pre="inhibit a variety of proinflammatory cytokines, including interferon, during viral" exact="infections" post="such as COVID-19 Ruxolitinib is a clinically approved Janus-associated"/>
 <result pre="for the interleukin-6 (IL-6) receptor; may potentially combat cytokine release" exact="syndrome" post="(CRS) and pulmonary symptoms in severely ill patients Sarilumab"/>
 <result pre="(IL-6) receptor; may potentially combat cytokine release syndrome (CRS) and" exact="pulmonary" post="symptoms in severely ill patients Sarilumab is an FDA"/>
 <result pre="antibody against the interleukin-6 receptor used for the treatment of" exact="rheumatoid arthritis." post="National Clinical Trial Identifier:(NCT04357808), (NCT04315298) 15. Sirolimus Immunosuppressive agent"/>
 <result pre="in patients treated with ACE inhibitors or ARBs.1, 4, 8" exact="Increased" post="expression of ACE2 may potentially facilitate COVID-19 infections.1 Renin"/>
 <result pre="a hypercoagulable state.Coagulation abnormalities observed in these patients include thrombotic" exact="disseminated intravascular coagulation" post="(DIC), venous thromboembolism, elevated D-dimer levels, high fibrinogen levels,"/>
 <result pre="observed in these patients include thrombotic disseminated intravascular coagulation (DIC)," exact="venous thromboembolism," post="elevated D-dimer levels, high fibrinogen levels, and microvascular thrombosis"/>
 <result pre="venous thromboembolism, elevated D-dimer levels, high fibrinogen levels, and microvascular" exact="thrombosis" post="in the pulmonary vasculature Heparin is clinically approved anti-coagulant."/>
 <result pre="D-dimer levels, high fibrinogen levels, and microvascular thrombosis in the" exact="pulmonary" post="vasculature Heparin is clinically approved anti-coagulant. National Clinical Trial"/>
 <result pre="plasma administration to COVID-19 patients has been shown to lessen" exact="viral" post="burden and enhance clinical status [90]. The likely mechanisms"/>
 <result pre="investigational convalescent plasma (COVID-19 convalescent plasma) [91]. Till date, a" exact="total" post="of 97 clinical trials for the use of convalescent"/>
 <result pre="Convalescent Plasma from Recovered COVID-19 Donors Institute of Liver and" exact="Biliary" post="Sciences, New Delhi, India Phase II(20) Completed NCT04346446 9."/>
 <result pre="COVID-19 The development of a new vaccine to contain COVID-19" exact="infection" post="is conceivably the safest way to end this pandemic."/>
 <result pre="shield against CoV as it has been seen that after" exact="infection" post="with CoVs, there may be chances of re-infection with"/>
 <result pre="prefusion stabilized spike protein 2019-nCoV National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), USA Phase I(45) Completed NCT04283461 3. Dose-Confirmation"/>
 <result pre="stabilized spike protein 2019-nCoV National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), USA Phase I(45) Completed NCT04283461 3. Dose-Confirmation Study"/>
 <result pre="Research Institute, Victoria, Australia Phase III(4170) On-going NCT04327206 11. Coronavirus" exact="Disease" post="(COVID-19) vaccineChAdOx1 nCoV-19 University of Oxford, United Kingdom Phase"/>
 <result pre="III(10260) On-going NCT04400838 13. Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus" exact="Type 5" post="Vector) CanSino Biologics Inc. Phase I(108) Completed NCT04313127 14."/>
 <result pre="and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2" exact="Infection" post="(COVID-19) Sinovac Research and Development Co., Ltd. Phase I(72)Phase"/>
 <result pre="perspectives and conclusion Despite enormous worldwide endeavors to restrict COVID-19" exact="infection" post="caused by SARS-CoV-2, the virus's spread has achieved an"/>
 <result pre="pathogens across the world. The source of the outbreak, the" exact="intermediate" post="host, an effective treatment regimen, tools for early diagnosis"/>
 <result pre="to specific ACE-2 receptors, which are widely expressed in the" exact="respiratory" post="tract, brain, liver, bile duct, lower GIT, and kidney."/>
 <result pre="widely expressed in the respiratory tract, brain, liver, bile duct," exact="lower" post="GIT, and kidney. Thus, all these organs remain on"/>
 <result pre="an efficient prevention system as well as medication for COVID-19" exact="pneumonia" post="is instantly required. Even though the development of COVIS-19"/>
 <result pre="the development of COVIS-19 therapeutics and vaccines is in its" exact="childhood" post="stage, but still researchers across the globe have met"/>
 <result pre="professionals are making use of the repurposed drugs (drugs with" exact="limited" post="proof for containing COVID-19) to prevent the spread of"/>
 <result pre="COVID-19, a mild environmental insight with special reference to IndiaSci." exact="Total" post="Environ.728202013891410.1016/j.scitotenv.2020.138914 4HassanS.A.SheikhF.N.JamalS.EzehJ.K.AkhtarA.Coronavirus (COVID-19): a review of clinical features, diagnosis,"/>
 <result pre="blood glucose management for the outbreak of 2019 novel coronavirus" exact="disease" post="(COVID-19) is urgently neededDiabetes Res. Clin. Pract.162202010811810.1016/j.diabres.2020.108118 8WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.ZhaoY.Clinical characteristics"/>
 <result pre="8WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.ZhaoY.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, ChinaJama32320201061106910.1001/jama.2020.1585 9WangY.WangY.ChenY.QinQ.Unique epidemiological and clinical features of"/>
 <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measuresJ. Med. Virol.92202056857610.1002/jmv.2574832134116 10Di Gennaro,"/>
 <result pre="Society of Great Britain and Ireland203200463163710.1002/path.1570 14JaimesJ.A.WhittakerG.R.Feline coronavirus: insights into" exact="viral" post="pathogenesis based on the spike protein structure and functionVirology517201810812110.1016/j.virol.2017.12.02729329682"/>
 <result pre="the renin-angiotensin system. Circ. Res.. doi:10.1161/CIRCRESAHA.120.317015. 17LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.ZhaoY.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin. Res. Cardiol.109202053153810.1007/s00392-020-01626-932161990 18LiH.LiuL.ZhangD.XuJ.DaiH.TangN.CaoB.SARS-CoV-2"/>
 <result pre="renin-angiotensin system. Circ. Res.. doi:10.1161/CIRCRESAHA.120.317015. 17LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.ZhaoY.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin. Res. Cardiol.109202053153810.1007/s00392-020-01626-932161990 18LiH.LiuL.ZhangD.XuJ.DaiH.TangN.CaoB.SARS-CoV-2 and viral"/>
 <result pre="metabolic diseases on COVID-19 in ChinaClin. Res. Cardiol.109202053153810.1007/s00392-020-01626-932161990 18LiH.LiuL.ZhangD.XuJ.DaiH.TangN.CaoB.SARS-CoV-2 and" exact="viral" post="sepsis: observations and hypothesesLancet202010.1016/S0140-6736(20)30920-X 19LiM.Y.LiL.ZhangY.WangX.S.Expression of the SARS-CoV-2 cell"/>
 <result pre="receptor gene ACE2 in a wide variety of human tissuesInfectious" exact="Diseases" post="of Poverty920201710.1186/s40249-020-00662-x31996251 20LiY.C.BaiW.Z.HashikawaT.The neuroinvasive potential of SARS-CoV2 may play"/>
 <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory" post="failure of COVID-19 patientsJ. Med. Virol.202010.1002/jmv.25728 21FuY.ChengY.WuY.Understanding SARS-CoV-2-mediated inflammatory"/>
 <result pre="87, 281â€&quot;286. http://doi.org/ 10.1007/s12098-020-03263-6. 23RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.109202010243310.1016/j.jaut.2020.102433 24ShereenM.A.KhanS.KazmiA.BashirN.SiddiqueR.COVID-19 infection: origin, transmission, and characteristics"/>
 <result pre="swine enteric coronaviruses differentially modulate PEDV replicationVirology5402020455610.1016/j.virol.2019.11.00731756532 30HackbartM.DengX.BakerS.C.Coronavirus endoribonuclease targets" exact="viral" post="polyuridine sequences to evade activating host sensorsProc. Natl. Acad."/>
 <result pre="sequences to evade activating host sensorsProc. Natl. Acad. Sci.1171420208094810310.1073/pnas.192148511732198201 31YanJ.GuoJ.FanC.JuanJ.YuX.LiJ.LeiD.Coronavirus" exact="disease" post="2019 (COVID-19) in pregnant women: a report based on"/>
 <result pre="with 2019 novel coronavirus in Wuhan, ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 38ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.17202025926010.1038/s41569-020-0360-532139904 39ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.ChenH.D.A pneumonia outbreak associated with a"/>
 <result pre="Wuhan, ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 38ZhengY.Y.MaY.T.ZhangJ.Y.XieX.COVID-19 and the cardiovascular systemNat. Rev. Cardiol.17202025926010.1038/s41569-020-0360-532139904 39ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.ChenH.D.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="new coronavirus of probable bat originNature579202027027310.1038/s41586-020-2012-732015507 40YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.LeeN.WuA.LeungC.B.SungJ.J.Cardiovascular complications of severe" exact="acute" post="respiratory syndromePostgrad. Med. J.82200614014410.1136/pgmj.2005.03751516461478 41Chinese Center for Disease Control"/>
 <result pre="coronavirus of probable bat originNature579202027027310.1038/s41586-020-2012-732015507 40YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.LeeN.WuA.LeungC.B.SungJ.J.Cardiovascular complications of severe acute" exact="respiratory" post="syndromePostgrad. Med. J.82200614014410.1136/pgmj.2005.03751516461478 41Chinese Center for Disease Control and"/>
 <result pre="of severe acute respiratory syndromePostgrad. Med. J.82200614014410.1136/pgmj.2005.03751516461478 41Chinese Center for" exact="Disease" post="Control and PreventionThe epidemiological characteristics of an outbreak of"/>
 <result pre="novel coronavirus diseases (COVID-19)â€&quot;China, 2020China CDC Weekly22020113122 42XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the" exact="cardiovascular" post="system: acute and long-term implicationsEur. Heart J.2020ehaa23110.1093/eurheartj/ehaa231 43SouthA.M.TomlinsonL.EdmonstonD.HiremathS.SparksM.A.Controversies of"/>
 <result pre="diseases (COVID-19)â€&quot;China, 2020China CDC Weekly22020113122 42XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the cardiovascular system:" exact="acute" post="and long-term implicationsEur. Heart J.2020ehaa23110.1093/eurheartj/ehaa231 43SouthA.M.TomlinsonL.EdmonstonD.HiremathS.SparksM.A.Controversies of reninâ€&quot;angiotensin system"/>
 <result pre="Weekly22020113122 42XiongT.Y.RedwoodS.PrendergastB.ChenM.Coronaviruses and the cardiovascular system: acute and long-term implicationsEur." exact="Heart" post="J.2020ehaa23110.1093/eurheartj/ehaa231 43SouthA.M.TomlinsonL.EdmonstonD.HiremathS.SparksM.A.Controversies of reninâ€&quot;angiotensin system inhibition during the COVID-19"/>
 <result pre="during the COVID-19 pandemicNat. Rev. Nephrol.202010.1038/s41581-020-0279-4 44SouthA.M.DizD.I.ChappellM.C.COVID-19, ACE2, and the" exact="cardiovascular" post="consequencesAm. J. Phys. Heart Circ. Phys.3182020H1084H109010.1152/ajpheart.00217.2020 45GuoJ.HuangZ.LinL.LvJ.Coronavirus disease 2019"/>
 <result pre="Rev. Nephrol.202010.1038/s41581-020-0279-4 44SouthA.M.DizD.I.ChappellM.C.COVID-19, ACE2, and the cardiovascular consequencesAm. J. Phys." exact="Heart" post="Circ. Phys.3182020H1084H109010.1152/ajpheart.00217.2020 45GuoJ.HuangZ.LinL.LvJ.Coronavirus disease 2019 (COVID-19) and cardiovascular disease:"/>
 <result pre="and the cardiovascular consequencesAm. J. Phys. Heart Circ. Phys.3182020H1084H109010.1152/ajpheart.00217.2020 45GuoJ.HuangZ.LinL.LvJ.Coronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular disease: a viewpoint on the"/>
 <result pre="J. Phys. Heart Circ. Phys.3182020H1084H109010.1152/ajpheart.00217.2020 45GuoJ.HuangZ.LinL.LvJ.Coronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="disease: a viewpoint on the potential influence of angiotensin-converting"/>
 <result pre="enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe" exact="acute" post="respiratory syndrome coronavirus 2 infectionJ. Am. Heart Assoc.92020e01621910.1161/JAHA.120.016219 46GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The"/>
 <result pre="inhibitors/angiotensin receptor blockers on onset and severity of severe acute" exact="respiratory" post="syndrome coronavirus 2 infectionJ. Am. Heart Assoc.92020e01621910.1161/JAHA.120.016219 46GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin,"/>
 <result pre="receptor blockers on onset and severity of severe acute respiratory" exact="syndrome" post="coronavirus 2 infectionJ. Am. Heart Assoc.92020e01621910.1161/JAHA.120.016219 46GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission"/>
 <result pre="severity of severe acute respiratory syndrome coronavirus 2 infectionJ. Am." exact="Heart" post="Assoc.92020e01621910.1161/JAHA.120.016219 46GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus"/>
 <result pre="Heart Assoc.92020e01621910.1161/JAHA.120.016219 46GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;an update on the statusMilitary Medical Research7202011010.1186/s40779-020-00240-031928528"/>
 <result pre="update on the statusMilitary Medical Research7202011010.1186/s40779-020-00240-031928528 47WuY.XuX.ChenZ.DuanJ.HashimotoK.YangL.YangC.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronavirusesBrain Behav. Immun.202010.1016/j.bbi.2020.03.031 48WuR.WangL.KuoH.C.ShannarA.PeterR.ChouP.J.LiS.HudlikarR.LiuX.LiuZ.PoianiG.J.An update"/>
 <result pre="COVID-19Current Pharmacology Reports62020567010.1007/s40495-020-00216-7 49MaoL.JinH.WangM.HuY.ChenS.HeQ.MiaoX.Neurologic manifestations of hospitalized patients with coronavirus" exact="disease" post="2019 in Wuhan, ChinaJAMA neurology202010.1001/jamaneurol.2020.1127 50XiangP.XuX.M.GaoL.L.WangH.Z.XiongH.F.LiR.H.First case of 2019"/>
 <result pre="in Wuhan, ChinaJAMA neurology202010.1001/jamaneurol.2020.1127 50XiangP.XuX.M.GaoL.L.WangH.Z.XiongH.F.LiR.H.First case of 2019 novel coronavirus" exact="disease" post="with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe acute respiratory syndrome coronavirus infection causes"/>
 <result pre="50XiangP.XuX.M.GaoL.L.WangH.Z.XiongH.F.LiR.H.First case of 2019 novel coronavirus disease with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe" exact="acute" post="respiratory syndrome coronavirus infection causes neuronal death in the"/>
 <result pre="case of 2019 novel coronavirus disease with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe acute" exact="respiratory" post="syndrome coronavirus infection causes neuronal death in the absence"/>
 <result pre="of 2019 novel coronavirus disease with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe acute respiratory" exact="syndrome" post="coronavirus infection causes neuronal death in the absence of"/>
 <result pre="novel coronavirus disease with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe acute respiratory syndrome coronavirus" exact="infection" post="causes neuronal death in the absence of encephalitis in"/>
 <result pre="disease with encephalitisChinaXiv202003202000015 51NetlandJ.MeyerholzD.K.MooreS.CassellM.PerlmanS.Severe acute respiratory syndrome coronavirus infection causes" exact="neuronal" post="death in the absence of encephalitis in mice transgenic"/>
 <result pre="acute respiratory syndrome coronavirus infection causes neuronal death in the" exact="absence of" post="encephalitis in mice transgenic for human ACE2J. Virol.8220087264727510.1128/JVI.00737-0818495771 52Li,"/>
 <result pre="syndrome coronavirus infection causes neuronal death in the absence of" exact="encephalitis" post="in mice transgenic for human ACE2J. Virol.8220087264727510.1128/JVI.00737-0818495771 52Li, K.,"/>
 <result pre="R., ... &amp;amp; McCray Jr, P. B. (2016). Middle East" exact="respiratory" post="syndrome coronavirus causes multiple organ damage and lethal disease"/>
 <result pre="... &amp;amp; McCray Jr, P. B. (2016). Middle East respiratory" exact="syndrome" post="coronavirus causes multiple organ damage and lethal disease in"/>
 <result pre="East respiratory syndrome coronavirus causes multiple organ damage and lethal" exact="disease" post="in mice transgenic for human dipeptidyl peptidase 4. J."/>
 <result pre="dipeptidyl peptidase 4. J. Infect. Dis. 213, 712â€&quot;722. doi:10.1093/infdis/jiv499. 53ChengY.LuoR.WangK.ZhangM.WangZ.DongL.XuG.Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19Kidney"/>
 <result pre="55YangX.YuY.XuJ.ShuH.LiuH.WuY.WangY.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir."/>
 <result pre="(2003). Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndrome. N. Engl. J. Med. 348, 1967- 1976."/>
 <result pre="Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndrome. N. Engl. J. Med. 348, 1967- 1976. doi:0.1056/NEJMoa030747."/>
 <result pre="1967- 1976. doi:0.1056/NEJMoa030747. 58PeirisJ.S.M.LaiS.T.PoonL.L.M.GuanY.YamL.Y.C.LimW.ChengV.C.C.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet36120031319132510.1016/S0140-6736(03)13077-212711465 59DuanZ.P.ChenY.ZhangJ.ZhaoJ.LangZ.W.MengF.K.BaoX.L.Clinical characteristics and mechanism of liver injury"/>
 <result pre="1976. doi:0.1056/NEJMoa030747. 58PeirisJ.S.M.LaiS.T.PoonL.L.M.GuanY.YamL.Y.C.LimW.ChengV.C.C.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet36120031319132510.1016/S0140-6736(03)13077-212711465 59DuanZ.P.ChenY.ZhangJ.ZhaoJ.LangZ.W.MengF.K.BaoX.L.Clinical characteristics and mechanism of liver injury in"/>
 <result pre="cause of severe acute respiratory syndromeLancet36120031319132510.1016/S0140-6736(03)13077-212711465 59DuanZ.P.ChenY.ZhangJ.ZhaoJ.LangZ.W.MengF.K.BaoX.L.Clinical characteristics and mechanism" exact="of liver" post="injury in patients with severe acute respiratory syndromeChin. J."/>
 <result pre="characteristics and mechanism of liver injury in patients with severe" exact="acute" post="respiratory syndromeChin. J. Hepatol.112003493496 60Lu, Y. C., Yin, C."/>
 <result pre="and mechanism of liver injury in patients with severe acute" exact="respiratory" post="syndromeChin. J. Hepatol.112003493496 60Lu, Y. C., Yin, C. B.,"/>
 <result pre="... &amp;amp; Jia, W. D. (2004). Clinical characteristics and mechanism" exact="of liver" post="function injury in 250 patients with severe acute respiratorv"/>
 <result pre="mechanism of liver function injury in 250 patients with severe" exact="acute" post="respiratorv syndrome. China Journal of Modern Medicine 14, 121â€&quot;123."/>
 <result pre="J. M., ... &amp;amp; Yan, H. Y. (2004). Clinical features" exact="of liver" post="injury in patients with severe acute respiratory syndrome. China"/>
 <result pre="(2004). Clinical features of liver injury in patients with severe" exact="acute" post="respiratory syndrome. China Journal of Modern Medicine, 2004, 46."/>
 <result pre="Clinical features of liver injury in patients with severe acute" exact="respiratory" post="syndrome. China Journal of Modern Medicine, 2004, 46. 62FarcasG.A.PoutanenS.M.MazzulliT.WilleyB.M.ButanyJ.AsaS.L.KainK.C.Fatal"/>
 <result pre="syndrome. China Journal of Modern Medicine, 2004, 46. 62FarcasG.A.PoutanenS.M.MazzulliT.WilleyB.M.ButanyJ.AsaS.L.KainK.C.Fatal severe" exact="acute" post="respiratory syndrome is associated with multiorgan involvement by coronavirusJ."/>
 <result pre="China Journal of Modern Medicine, 2004, 46. 62FarcasG.A.PoutanenS.M.MazzulliT.WilleyB.M.ButanyJ.AsaS.L.KainK.C.Fatal severe acute" exact="respiratory" post="syndrome is associated with multiorgan involvement by coronavirusJ. Infect."/>
 <result pre="Journal of Modern Medicine, 2004, 46. 62FarcasG.A.PoutanenS.M.MazzulliT.WilleyB.M.ButanyJ.AsaS.L.KainK.C.Fatal severe acute respiratory" exact="syndrome" post="is associated with multiorgan involvement by coronavirusJ. Infect. Dis.191200519319710.1086/42687015609228"/>
 <result pre="is associated with multiorgan involvement by coronavirusJ. Infect. Dis.191200519319710.1086/42687015609228 63ChauT.N.LeeK.C.YaoH.TsangT.Y.ChowT.C.YeungY.C.LaiC.L.SARS-associated" exact="viral hepatitis" post="caused by a novel coronavirus: report of three casesHepatology39200430231010.1002/hep.2011114767982"/>
 <result pre="associated with multiorgan involvement by coronavirusJ. Infect. Dis.191200519319710.1086/42687015609228 63ChauT.N.LeeK.C.YaoH.TsangT.Y.ChowT.C.YeungY.C.LaiC.L.SARS-associated viral" exact="hepatitis" post="caused by a novel coronavirus: report of three casesHepatology39200430231010.1002/hep.2011114767982"/>
 <result pre="64TanY.J.FieldingB.C.GohP.Y.ShenS.TanT.H.LimS.G.HongW.Overexpression of 7a, a protein specifically encoded by the severe" exact="acute" post="respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathwayJ."/>
 <result pre="of 7a, a protein specifically encoded by the severe acute" exact="respiratory" post="syndrome coronavirus, induces apoptosis via a caspase-dependent pathwayJ. Virol.782004140431404710.1128/JVI.78.24.14043-14047.200415564512"/>
 <result pre="7a, a protein specifically encoded by the severe acute respiratory" exact="syndrome" post="coronavirus, induces apoptosis via a caspase-dependent pathwayJ. Virol.782004140431404710.1128/JVI.78.24.14043-14047.200415564512 65Guan,"/>
 <result pre="&amp;amp; Du, B. (2020). Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in China. MedRxiv. doi:10.1056/NEJMoa2002032. 66Chai, X., Hu, L., Zhang,"/>
 <result pre="67LiuJ.LiS.LiuJ.LiangB.WangX.WangH.XiongL.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the" exact="peripheral" post="blood of SARS-CoV-2 infected patientsEBioMedicine55202010276310.1016/j.ebiom.2020.102763 68XuJ.ZhaoS.TengT.AbdallaA.E.ZhuW.XieL.GuoX.Systematic comparison of two"/>
 <result pre="coronaviruses: SARS-CoV-2 and SARS-CoVViruses12202024410.3390/v12020244 69XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.TaiY.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.8202042042210.1016/S2213-2600(20)30076-X32085846 70CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.YipC.C.Gastrointestinal manifestations of SARS-CoV-2"/>
 <result pre="SARS-CoV-2 and SARS-CoVViruses12202024410.3390/v12020244 69XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.TaiY.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.8202042042210.1016/S2213-2600(20)30076-X32085846 70CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.YipC.C.Gastrointestinal manifestations of SARS-CoV-2 infection"/>
 <result pre="acute respiratory distress syndromeLancet Respir. Med.8202042042210.1016/S2213-2600(20)30076-X32085846 70CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.YipC.C.Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the Hong"/>
 <result pre="Kong cohort and systematic review and meta-analysisGastroenterology202010.1053/j.gastro.2020.03.065 71PetrieJ.R.GuzikT.J.TouyzR.M.Diabetes, hypertension, and" exact="cardiovascular" post="disease: clinical insights and vascular mechanismsCan. J. Cardiol.34201857558410.1016/j.cjca.2017.12.00529459239 72Schoen,"/>
 <result pre="and meta-analysisGastroenterology202010.1053/j.gastro.2020.03.065 71PetrieJ.R.GuzikT.J.TouyzR.M.Diabetes, hypertension, and cardiovascular disease: clinical insights and" exact="vascular" post="mechanismsCan. J. Cardiol.34201857558410.1016/j.cjca.2017.12.00529459239 72Schoen, K., Horvat, N., Guerreiro, N."/>
 <result pre="MERS, thrusting coronaviruses into the spotlightViruses1120195910.3390/v11010059 74YangJ.K.FengY.YuanM.Y.YuanS.Y.FuH.J.WuB.Y.XuX.Plasma glucose levels and" exact="diabetes" post="are independent predictors for mortality and morbidity in patients"/>
 <result pre="MoreiraN.C.COVID-19 and diabetes: knowledge in progressDiabetes Res. Clin. Pract.162202010814210.1016/j.diabres.2020.108142 77International" exact="Diabetes" post="Federation, 2020. https://diabetesvoice.org/en/news/covid-19-and-diabetes/. 78JamiesonD.J.TheilerR.N.RasmussenS.A.Emerging infections and pregnancyEmerg. Infect. Dis.122006163810.3201/eid1211.06015217283611"/>
 <result pre="progressDiabetes Res. Clin. Pract.162202010814210.1016/j.diabres.2020.108142 77International Diabetes Federation, 2020. https://diabetesvoice.org/en/news/covid-19-and-diabetes/. 78JamiesonD.J.TheilerR.N.RasmussenS.A.Emerging" exact="infections" post="and pregnancyEmerg. Infect. Dis.122006163810.3201/eid1211.06015217283611 79LuoY.YinK.Management of pregnant women infected"/>
 <result pre="their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus" exact="infections" post="and pregnancy outcomesArchives of pathology &amp;amp; laboratory medicine202010.5858/arpa.2020-0901-SA 81GajbhiyeR.ModiD.MahaleS.Pregnancy"/>
 <result pre="without underlying diseases in pandemic epicentersmedRxiv202010.1101/2020.04.05.20054361 85SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJama202010.1001/jama.2020.6019 86https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. 87https://www.europeanpharmaceuticalreview.com/news/121787/glenmark-approved-to-supply-favipiravir-as-covid-19-treatment-in-india/. 88https://www.ashp.org/-/media/assets/pharmacy-practice/resourcecenters/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx?. 89KeithP.DayM.PerkinsL.MoyerL.HewittK.WellsA.A novel"/>
 <result pre="of preterm birthLancet3712008758410.1016/S0140-6736(08)60074-418177778 94WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE 2 G8790A polymorphism: involvement in" exact="type 2" post="diabetes mellitus combined with cerebral strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033"/>
 <result pre="birthLancet3712008758410.1016/S0140-6736(08)60074-418177778 94WuY.H.LiJ.Y.WangC.ZhangL.M.QiaoH.The ACE 2 G8790A polymorphism: involvement in type 2" exact="diabetes mellitus" post="combined with cerebral strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033 95DingY.HeL.ZhangQ.Organ distribution"/>
 <result pre="G8790A polymorphism: involvement in type 2 diabetes mellitus combined with" exact="cerebral" post="strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033 95DingY.HeL.ZhangQ.Organ distribution of severe acute"/>
 <result pre="with cerebral strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033 95DingY.HeL.ZhangQ.Organ distribution of severe" exact="acute" post="respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients:"/>
 <result pre="cerebral strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033 95DingY.HeL.ZhangQ.Organ distribution of severe acute" exact="respiratory" post="syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications"/>
 <result pre="strokeJ. Clin. Lab. Anal.312017e2203310.1002/jcla.22033 95DingY.HeL.ZhangQ.Organ distribution of severe acute respiratory" exact="syndrome" post="(SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for"/>
</results>
